Table 3. Vaccination of Patients With Cancer
Recommendation
(Strength, Evidence Quality)
Vaccine
Prior to or During
Chemotherapy
a
Starting ≥3 Months
Postchemotherapy and ≥6
Months After Anti–B-Cell
Antibodies for Inactivated
Vaccines (see each live
vaccine for interval)
H influenzae type b
conjugate
U (WR-L) U (SR-M)
Hepatitis A U (WR-L) U (SR-VL)
Hepatitis B U (WR-L) U (SR-M)
R: adults (SR-VL)
DTaP, Tdap U (WR-L) U: age 0-18 y (SR-M)
R: adults with acute
lymphoblastic leukemia or
lymphoma (WR-VL)
HPV U: age 11-26 y (WR-VL) U (SR-VL)
Influenza, inactivated U (SR-L to M) U
b
(SR-M)
Influenza, live attenuated X (WR-VL) U (SR-L)
MMR, live X
c
(SR-M) Starting at 3 mo: U (SR-L)
MMRV, live X
c
(SR-M) Starting at 3 mo: U (WR-VL)
Meningococcal conjugate U (WR-L) U (SR-L)
Pneumococcal conjugate-13
(PCV13)
R (SR-L)
R: age ≥6 y
d
(SR-VL)
U (SR-L)
Pneumococcal
polysaccharide (PPSV23)
R: age ≥2 y (SR-L) U (SR-L)
Poliovirus, inactivated U (WR-L) U (SR-L)
Rotavirus, live X (SR-VL) Not applicable
Varicella, live X
c
(SR-M) Starting at 3 mo: U
e
(WR-VL)
Zoster, live X
c
(SR-VL) Starting at 3 mo: U
e
(WR-VL)
15
Continued on next page
